DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

Phase 3

Completed

• Conditions: Cardiac Disease
• Interventions: Drug: DEFINITY®

• Registration Number: NCT03719612
• Lead Sponsor: Lantheus Medical Imaging

Brief Summary

This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as compared with non-contrast cardiac magnetic resonance imaging (CMR) used as the truth standard.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-09-28
• Study First Submitted QC: 2018-10-23
• Study First Posted: 2018-10-25
• Study Start: 2018-12-28
• Status Verified: 2019-11
• Primary Completion: 2020-01-09
• Study Completion: 2020-01-09
• Results First Submitted: 2020-12-11
• Results First Submitted QC: 2020-12-11
• Results First Posted: 2021-01-07
• Last Update Submitted: 2021-01-07
• Last Update Posted: 2021-01-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

1. Men and women ≥ 18 years of age in sinus rhythm
2. Able to communicate effectively with trial personnel
3. LVEF measurements obtained via 2D Echo with or without contrast obtained within 6 months prior to enrollment (Day 0)
4. Has provided signed informed consent after receiving a verbal and written explanation of this clinical trial

Read More

Exclusion Criteria

1. Female subjects who are pregnant or lactating. All women of child bearing potential [WOCBP] must have a negative urine pregnancy test at screening regardless of contraceptive use history.

2. Women of child-bearing potential are excluded unless they:

   1. are post-menopausal defined as amenorrhea ≥ 12 consecutive months, OR
   2. have undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy), OR
   3. have been using an adequate and medically approved method of contraception to avoid pregnancy for at least 1 month prior to DEFINITY® dose administration and be willing to continue using the same method for the duration of the study.

3. Current illness or pathology that would prevent undergoing investigational product administration due to a significant safety risk to the patient.

4. Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic blood pressure ≤ 90 mmHg).

5. Unstable cardiovascular status defined as:

   1. myocardial infarction or unstable angina pectoris within 6 months prior to enrollment/DEFINITY® dose administration day
   2. transient ischemic attack or stroke within 3 months prior to DEFINITY® dose administration
   3. symptomatic valvular heart disease or moderate to severe stenotic valvular heart disease
   4. clinically significant congenital heart defects
   5. current uncontrolled cardiac arrhythmias causing symptoms or hemodynamic compromise
   6. acute pulmonary embolus or pulmonary infarction
   7. acute myocarditis or pericarditis
   8. acute aortic dissection
   9. atrial fibrillation

6. any major surgery within 4 weeks prior to screening

7. known contraindications to undergoing CMR (e.g. implanted pacemakers, cardioverter, defibrillators) or claustrophobia

8. participation in any investigational drug, device, or placebo study within 30 days prior to screening

9. known hypersensitivity to perflutren, or any of the excipients in DEFINITY®

10. prisoners or those who are subject to compulsory detention or involuntary incarceration for treatment of either a psychiatric or physical illness (e.g., infectious disease).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
DEFINITY®	DEFINITY®	Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound

Primary Outcome Measures

Name	Time	Method
Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader	Up to 30 days between day of echocardiograms and CMR imaging	Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography by comparing LVEF percentage differences from CMR measured by 3 independent blinded image readers.

Secondary Outcome Measures

Name	Time	Method
Secondary Objective 5: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms	Up to 30 days between day of echocardiograms and CMR imaging	Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.
Secondary Objective 1: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader for Sub-optimal Echocardiograms	Up to 30 days between day of echocardiogram and CMR imaging	Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography in subjects with suboptimal echocardiograms by comparing LVEF percentage differences from CMR measured by 3 independent blinded readers.
Secondary Objective 2: Absolute Value LVEF Percentage Differences From CMR Between Blinded Readers	Up to 30 days between day of echocardiograms and CMR imaging	Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF percentage differences from CMR between 3 independent blinded readers.
Secondary Objective 3: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers	Up to 30 days between day of echocardiogram and CMR imaging	Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers.
Secondary Objective 4: Absolute Value of LVEF Percentage Differences From CMR Between Readers for Sub-optimal Echocardiograms	Up to 30 days between day of echocardiograms and CMR imaging	Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF percentage differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.

Trial Locations

Locations (15)

Banner University of Arizona Medical Center; 🇺🇸 Tucson, Arizona, United States

Cedars Sinai; 🇺🇸 Los Angeles, California, United States

University of California-Irvine; 🇺🇸 Orange, California, United States

Alfieri Cardiology; 🇺🇸 Wilmington, Delaware, United States

University of Oklahoma; 🇺🇸 Oklahoma City, Oklahoma, United States

Indiana University; 🇺🇸 Bloomington, Indiana, United States

Baptist Hospital; 🇺🇸 Paducah, Kentucky, United States

Baylor Scott White Research Institute; 🇺🇸 Temple, Texas, United States

UC San Diego; 🇺🇸 San Diego, California, United States

Northwestern Medical Group; 🇺🇸 Chicago, Illinois, United States

Mercy Unit Hospital; 🇺🇸 Coon Rapids, Minnesota, United States

Oregon Health and Sciences University; 🇺🇸 Portland, Oregon, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

University of Cincinnati Medical Center; 🇺🇸 Cincinnati, Ohio, United States

Albert Einstein Medical Center; 🇺🇸 Philadelphia, Pennsylvania, United States